Ovid Therapeutics Inc. (OVID) Reports Q2 EPS of $0.12
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- Wall St climbs after August inflation report, oil price slide
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but on track for 8% weekly gain on supply concerns; US diesel hits record high
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
BTIG Reiterates Buy Rating on Ovid Therapeutics Inc (OVID)
August 14, 2024 6:13 AM EDTBTIG analyst Thomas Shrader reiterated a Buy rating and $5.00 price target on Ovid Therapeutics Inc (NASDAQ: OVID).
The analyst comments "The P2 trial for OV888 in CCM is expected to start in 2H24 and could rapidly establish POC. The lesions (complex blood vessel tangles) are clearly visible in patients and treatment with OV888 has the chance to resolve them (not certain but seen in animal models). Similarly, OV329 is a safer Vigabatrin by design, so confirming safety in humans is highly de-risking, we believe. We hosted OVID management at the recent BTIG... More
